ProShare Advisors
ABVX

ProShare Advisors’s Abivax ABVX Stock Holding History

ProShare Advisors’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$306K Buy
2,748
+141
+5% +$16.7K ﹤0.01% 1327
2025
Q4 		$352K Buy
+2,607
New +$284K ﹤0.01% 1357

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

ProShare Advisors's ABVX Position: Q1 2026 in Review

ProShare Advisors increased its Abivax (ABVX) stake by 5.4% in Q1 2026, buying an estimated $16.7K and bringing the position to 2,748 shares worth $306K. The position accounts for ﹤0.01% of the portfolio, ranked #1327.

ProShare Advisors first reported a position in ABVX in Q4 2025 and has held it in 2 quarters since. The position peaked at $352K in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • ProShare Advisors held 2,748 shares of Abivax worth $306K as of Q1 2026.
  • ProShare Advisors bought 141 Abivax shares in Q1 2026, an estimated $16.7K.
  • Abivax made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1327 holding.
  • ProShare Advisors first reported a position in Abivax in Q4 2025 and has held it in 2 quarters since.
  • ProShare Advisors's Abivax position peaked at $352K in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.